Novel agents for the treatment of childhood acute leukemia

Colleen E. Annesley, Patrick A Brown

Research output: Contribution to journalReview article

Abstract

Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.

Original languageEnglish (US)
Pages (from-to)61-79
Number of pages19
JournalTherapeutic Advances in Hematology
Volume6
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Epigenomics
Leukemia
Pediatrics
Janus Kinases
Histone Deacetylase Inhibitors
Methyltransferases
Proteasome Endopeptidase Complex
Sirolimus
Regulator Genes
T-Cell Antigen Receptor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Immunotherapy
Immunity
Neoplasms
Monoclonal Antibodies
T-Lymphocytes
Gene Expression
Antibodies

Keywords

  • ALL
  • AML
  • blinatumomab
  • CAR T-cells
  • carfilzomib
  • EPZ-5676
  • FLT3
  • moxetumomab

ASJC Scopus subject areas

  • Hematology

Cite this

Novel agents for the treatment of childhood acute leukemia. / Annesley, Colleen E.; Brown, Patrick A.

In: Therapeutic Advances in Hematology, Vol. 6, No. 2, 2015, p. 61-79.

Research output: Contribution to journalReview article

@article{c40bb2a9843e40cdb542c219a7d60783,
title = "Novel agents for the treatment of childhood acute leukemia",
abstract = "Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.",
keywords = "ALL, AML, blinatumomab, CAR T-cells, carfilzomib, EPZ-5676, FLT3, moxetumomab",
author = "Annesley, {Colleen E.} and Brown, {Patrick A}",
year = "2015",
doi = "10.1177/2040620714565963",
language = "English (US)",
volume = "6",
pages = "61--79",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
publisher = "Sage Publications",
number = "2",

}

TY - JOUR

T1 - Novel agents for the treatment of childhood acute leukemia

AU - Annesley, Colleen E.

AU - Brown, Patrick A

PY - 2015

Y1 - 2015

N2 - Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.

AB - Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.

KW - ALL

KW - AML

KW - blinatumomab

KW - CAR T-cells

KW - carfilzomib

KW - EPZ-5676

KW - FLT3

KW - moxetumomab

UR - http://www.scopus.com/inward/record.url?scp=84993813859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993813859&partnerID=8YFLogxK

U2 - 10.1177/2040620714565963

DO - 10.1177/2040620714565963

M3 - Review article

VL - 6

SP - 61

EP - 79

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 2

ER -